Tizona Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 46

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 11

Tizona Therapeutics General Information

Description

Operator of an immunology company intended to harness the power of the immune system to develop treatments for cancer and autoimmune diseases. The company's treatments are designed to modulate the activity of immunosuppressive cells by targeting the cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment, enabling patients to get complete and durable remissions for cancer and autoimmune diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 611 Gateway Boulevard
  • Suite 221
  • San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 611 Gateway Boulevard
  • Suite 221
  • San Francisco, CA 94080
  • United States
+1 (650)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tizona Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Secondary Transaction - Private Completed Clinical Trials - Phase 1
8. Later Stage VC 21-Jul-2020 Completed Clinical Trials - Phase 1
7. Later Stage VC (Series B3) 10-Jan-2019 Completed Clinical Trials - Phase 1
6. Later Stage VC 03-Jan-2019 Completed Clinical Trials - Phase 1
5. Debt - General 06-Sep-2018 Completed Pre-Clinical Trials
4. Early Stage VC (Series B2) 04-Aug-2017 Completed Pre-Clinical Trials
3. Early Stage VC (Series B) 23-Feb-2016 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 17-Sep-2015 $27M $27M Completed Startup
1. Accelerator/Incubator 31-Jul-2015 Completed Startup
To view Tizona Therapeutics’s complete valuation and funding history, request access »

Tizona Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B3
Series B2
Series B 13,333,332 $0.000100 $0.01 $1.5 $1.5 1x $1.5 13.33%
Series A 27,217,500 $0.000100 $0.08 $1 $1 1x $1 27.22%
To view Tizona Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Tizona Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of an immunology company intended to harness the power of the immune system to develop treatments for cancer an
Drug Discovery
San Francisco, CA
46 As of 2025

London, Canada
 

Philadelphia, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tizona Therapeutics Competitors (54)

One of Tizona Therapeutics’s 54 competitors is Sernova, a Corporation company based in London, Canada.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sernova Corporation London, Canada
Aro Biotherapeutics Venture Capital-Backed Philadelphia, PA
NexImmune Formerly VC-backed Gaithersburg, MD
Senti Bio Formerly VC-backed South San Francisco, CA
Adimab Venture Capital-Backed Lebanon, NH
You’re viewing 5 of 54 competitors. Get the full list »

Tizona Therapeutics Patents

Tizona Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023250952-A1 Combination therapy involving anti-hla-g antibodies and anti-egfr antibodies, anti-pd1 or anti-pd-l1 antibodies, and/or anti-cd47 Pending 08-Apr-2022
EP-4504345-A1 Combination therapy involving anti-hla-g antibodies and anti-egfr antibodies, anti-pd1 or anti-pd-l1 antibodies, and/or anti-cd47 Pending 08-Apr-2022
AU-2021286650-A1 Bispecific immune cell engagers with binding specificity for hla-g and another antigen Inactive 11-Jun-2020
CA-3180883-A1 Bispecific immune cell engagers with binding specificity for hla-g and another antigen Pending 11-Jun-2020
EP-4165081-A2 Bispecific immune cell engagers with binding specificity for hla-g and another antigen Pending 11-Jun-2020 C07K16/2833
To view Tizona Therapeutics’s complete patent history, request access »

Tizona Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tizona Therapeutics Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
AbbVie Ventures Corporate Venture Capital Minority
Gilead Sciences Corporation Minority
AbbVie Corporation Minority
InterWest Partners Venture Capital Minority
Abingworth Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Tizona Therapeutics FAQs

  • When was Tizona Therapeutics founded?

    Tizona Therapeutics was founded in 2014.

  • Where is Tizona Therapeutics headquartered?

    Tizona Therapeutics is headquartered in San Francisco, CA.

  • What is the size of Tizona Therapeutics?

    Tizona Therapeutics has 46 total employees.

  • What industry is Tizona Therapeutics in?

    Tizona Therapeutics’s primary industry is Drug Discovery.

  • Is Tizona Therapeutics a private or public company?

    Tizona Therapeutics is a Private company.

  • What is Tizona Therapeutics’s current revenue?

    The current revenue for Tizona Therapeutics is .

  • How much funding has Tizona Therapeutics raised over time?

    Tizona Therapeutics has raised $520M.

  • Who are Tizona Therapeutics’s investors?

    AbbVie Ventures, Gilead Sciences, AbbVie, InterWest Partners, and Abingworth are 5 of 11 investors who have invested in Tizona Therapeutics.

  • Who are Tizona Therapeutics’s competitors?

    Sernova, Aro Biotherapeutics, NexImmune, Senti Bio, and Adimab are some of the 54 competitors of Tizona Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »